Literature DB >> 19270472

Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.

Ben Colagiuri1, Kirsten Morley, Robert Boakes, Paul Haber.   

Abstract

BACKGROUND: Double-blind placebo-controlled trials are intended to control for the impact of expectancy on outcomes. Whether they always achieve this is, however, questionable.
METHODS: Reanalysis of a clinical trial of naltrexone and acamprosate for alcohol dependence investigated this issue further. In this trial, 169 alcohol-dependent patients received naltrexone, acamprosate or placebo for 12 weeks. In addition to being assessed on various indices of alcohol dependence, they were asked whether they believed they received active medication or placebo.
RESULTS: While there were no differences in outcomes between treatment groups, those who believed they had been taking active medication consumed fewer alcoholic drinks and reported less alcohol dependence and cravings. That is, irrespective of actual treatment, perceived medication allocation predicted health outcomes.
CONCLUSIONS: These results highlight the differences between treatment administration in clinical trials and standard medical practice, a discrepancy that may sometimes decrease the validity of these types of trials. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270472     DOI: 10.1159/000206871

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  9 in total

1.  A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response.

Authors:  Jon E Grant; Brian L Odlaug; Samuel R Chamberlain; Suck Won Kim
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

2.  Perceived treatment, feedback, and placebo effects in double-blind RCTs: an experimental analysis.

Authors:  Ben Colagiuri; Robert A Boakes
Journal:  Psychopharmacology (Berl)       Date:  2009-12-09       Impact factor: 4.530

3.  Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.

Authors:  Daniel J Fridberg; Dingcai Cao; Jon E Grant; Andrea C King
Journal:  Alcohol Clin Exp Res       Date:  2014-10-21       Impact factor: 3.455

4.  Randomized controlled trial examining expectancy effects on the accuracy of weight measurement.

Authors:  G R Dutton; K R Fontaine; A S Alcorn; J Dawson; P L Capers; D B Allison
Journal:  Clin Obes       Date:  2014-12-22

Review 5.  Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions.

Authors:  Kenneth E Freedland; David C Mohr; Karina W Davidson; Joseph E Schwartz
Journal:  Psychosom Med       Date:  2011-05-02       Impact factor: 4.312

6.  Adherence, expectations and the placebo response: why is good adherence to an inert treatment beneficial?

Authors:  Cinnamon Stetler
Journal:  Psychol Health       Date:  2013-08-26

7.  Influence of methylphenidate treatment assumptions on cognitive function in healthy young adults in a double-blind, placebo-controlled trial.

Authors:  Jean-Luc Mommaerts; Gerlinde Beerens; Lieve Van den Block; Eric Soetens; Sandrina Schol; Erwin Van De Vijver; Dirk Devroey
Journal:  Psychol Res Behav Manag       Date:  2013-08-27

8.  Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial.

Authors:  Kirsten C Morley; Paul S Haber; Madeleine L Morgan; Fares Samara
Journal:  Subst Abuse Rehabil       Date:  2012-05-28

9.  Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression.

Authors:  Johannes A C Laferton; Sagar Vijapura; Lee Baer; Alisabet J Clain; Abigail Cooper; George Papakostas; Lawrence H Price; Linda L Carpenter; Audrey R Tyrka; Maurizio Fava; David Mischoulon
Journal:  Front Psychiatry       Date:  2018-09-07       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.